Get the Stockscreener App
0.5128
0.06%
-0.0003
After Hours:
.51
-0.0028
-0.55%
Femasys Inc stock is traded at $0.5128, with a volume of 305.57K.
It is down -0.06% in the last 24 hours and down -9.17% over the past month.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
See More
Previous Close:
$0.5131
Open:
$0.53
24h Volume:
305.57K
Relative Volume:
0.38
Market Cap:
$30.51M
Revenue:
$2.06M
Net Income/Loss:
$-19.80M
P/E Ratio:
-0.7119
EPS:
-0.7203
Net Cash Flow:
$-20.12M
1W Performance:
-14.53%
1M Performance:
-9.17%
6M Performance:
+48.64%
1Y Performance:
-67.95%
1-Day Range:
$0.5005
$0.53
1-Week Range:
$0.5005
$0.596
52-Week Range:
$0.3067
$1.60
Femasys Inc Stock (FEMY) Company Profile
Name
Femasys Inc
Sector
Industry
Phone
770-500-3910
Address
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
0.5128 | 30.53M | 2.06M | -19.80M | -20.12M | -0.7203 |
ISRG
Intuitive Surgical Inc
|
469.98 | 167.61B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
158.27 | 44.35B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
75.26 | 36.19B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
42.67 | 34.11B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
226.31 | 33.24B | 5.40B | 1.49B | 1.78B | 10.12 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | Laidlaw | Buy |
Femasys Inc Stock (FEMY) Latest News
Femasys (NASDAQ: FEMY) director discloses notes, warrants and share stake - Stock Titan
Femasys Inc. Enters Omnibus Amendment and Issues Series D-1 Warrants – SEC 8-K Filing March 2026 - Minichart
Femasys amends warrants and notes, appoints new director to board - Investing.com
Femasys (NASDAQ: FEMY) director receives stock options for 35,200 shares - Stock Titan
Femasys Amends Financing Terms and Issues New Warrants - TipRanks
Femasys enters omnibus amendment and consent agreement on March 19, 2026SEC filing - marketscreener.com
Femasys Enters Omnibus Amendment And Consent Agreement On March 19, 2026SEC Filing - TradingView
Femasys Amends Notes and Warrants; Issues 16.38M New Warrants at $0.58 to Holders - TradingView
Femasys (FEMY) grants 16.4M Series D-1 warrants and appoints new independent director - Stock Titan
Femasys Inc. announced that it has received $12 million in funding - marketscreener.com
Femasys appoints anesthesiologist to board of directors By Investing.com - Investing.com South Africa
PharmaCyte Biotech (PMCB) logs neutral Form 4 as 10% FEMASYS (FEMY) owner - Stock Titan
Femasys (NASDAQ: FEMY) director Joshua Silverman files neutral Form 4 - Stock Titan
PharmaCyte Biotech (FEMY) reports 7.87% stake including warrants - Stock Titan
Femasys Inc. Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - marketscreener.com
Femasys appoints anesthesiologist to board of directors - Investing.com
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - Bitget
Femasys Inc. Appoints Kenneth D. Eichenbaum, M.D., M.S.E., to Board of Directors - Quiver Quantitative
Femasys appoints Dr. Kenneth D. Eichenbaum to board of directors - marketscreener.com
Femasys Appoints Dr. Kenneth D. Eichenbaum To Board Of Directors - TradingView
Femasys begins enrollment in pivotal trial for FemBloc device - Investing.com Nigeria
Jeremy Alexander Sipos Net Worth (2026) - GuruFocus
Femasys gets FDA OK for final FemBloc trial, secures $12M financing, stock surges - MSN
Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing - MSN
Femasys begins enrollment in pivotal trial for FemBloc device By Investing.com - Investing.com Australia
Non-surgical permanent birth control FemBloc begins final U.S. trial - Stock Titan
Femasys Inc. (NASDAQ:FEMY) Receives $5.50 Average Price Target from Analysts - Defense World
Femasys (NASDAQ:FEMY) Now Covered by Analysts at Lake Street Capital - Defense World
Lake Street initiates Femasys stock coverage with buy rating By Investing.com - Investing.com Australia
Lake Street initiates Femasys stock coverage with buy rating - Investing.com
FEMY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
FEMY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
FEMY Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Femasys’s FemBloc Pivotal Trial Update: What Investors Should Watch in Women’s Health - TipRanks
Femasys Announces FemBloc® Permanent Birth Control Has - GlobeNewswire
New non-surgical permanent birth control clears key global quality hurdle - Stock Titan
Femasys Announces FemBloc Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access - Bitget
Sentiment Watch: Is Femasys Inc stock undervalued right nowJuly 2025 Setups & Low Risk Investment Opportunities - baoquankhu1.vn
Femasys receives CPT code approval for infertility treatment - Investing.com India
Femasys receives CPT code approval for infertility treatment By Investing.com - Investing.com Australia
FEMY SEC FilingsFEMASYS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Trend Review: Can Femasys Inc benefit from deglobalization2025 Big Picture & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
AMA procedure code supports new infertility option for over 10M US women - Stock Titan
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination - Bitget
Femasys (FEMY) CEO awarded 729,000 RSUs vesting through 2027 - Stock Titan
Femasys (NASDAQ: FEMY) CFO receives 342,000 restricted stock units - Stock Titan
Femasys (FEMY) CTO reports common stock and option holdings in Form 3 - Stock Titan
How cyclical is Femasys Inc.’s revenue streamJuly 2025 News Drivers & Technical Pattern Based Buy Signals - mfd.ru
Femasys : Shareholder Update – 2025 in Review - marketscreener.com
Femasys Inc Stock (FEMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):